Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis—Coordinating Research Priorities to Move the Field Forward
Elizabeth J. Phillips, Charles S. Bouchard, Sherrie J. Divito
Abstract
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is the most life-threatening disease managed by dermatologists. Although SJS/TEN only affects 1 to 5 million people per year, mortality remains stable at 15%, and to our knowledge, high-level evidence-based treatment options are lacking. The SJS/TEN meeting1,2 that was held virtually August 28 and 29, 2021, brought together multidisciplinary clinicians, scientists, and community members to share knowledge, research, stories, and support. In this Viewpoint, we provide our perspective of the successes and gaps in research and clinical care of SJS/TEN that were highlighted at this meeting and propose future opportunities for prioritization and optimization.